Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial.
Gia Toan Tang, Shalem Leemaqz, Bevin Bhoyrul et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of sublingual minoxidil in treating mild androgenetic alopecia in transgender individuals undergoing testosterone therapy. Among 46 participants, those receiving minoxidil showed a significant increase in midfrontal hair count (+15.7 hairs/cm²) compared to placebo at 24 weeks, indicating its potential as a treatment option.
Key findings
- Midfrontal hair count improved by +15.7 hairs/cm² with minoxidil vs placebo at Week 24 (P = .03).
- In the open-label phase, midfrontal improvement from Week 0 to 48 was +12.3 hairs/cm² (P = .02).
- Significant vertex hair count gains were observed by Week 48, with an increase of +37.9 hairs/cm² (P = .009).
Why it matters
The study highlights a treatment alternative for androgenetic alopecia in transgender individuals on testosterone therapy, addressing a common concern without interfering with masculinization.
What to keep in mind
Mild baseline androgenetic alopecia may have limited the detection of changes in global photographs and quality-of-life scores.